It was noticed that the diagnostic performance of the biomarker panel for early-stage lung cancer was better than that of each biomarker alone [Fig. 4A, biomarker panel (AUC=0.78) vs. Pro-SFTPB (AUC=0.73), P<0.0001; biomarker panel (AUC=0.78) vs. CA125 (AUC=0.70), P<0.001; biomarker panel (AUC=0.78) vs. Cyfra21-1 (AUC=0.68), P<0.001; biomarker panel (AUC=0.78) vs. CEA (AUC=0.61), P<0.0001]. Here, CEACAM5 is linked to lung carcinoma.